Sophrosyne is Led by Top-tier Executives with Clear Focus & Passion on Execution and Building Enterprise Value
Chief Executive Officer
Chief Medical Officer
Chief Development Officer
Chemistry Lead
Head of Toxicology
Chief of Staff
Finance Lead
Project Management Lead
Marketing Lead
CEO of DRW
President at DRW
Founder and Chairman of Sophrosyne
Chief Executive Officer
Addiction Psychiatrist and Clinical Neuroscientist
Psychiatrist, Addiction Physician, Business Leader
Professor in the Departments of Behavioral Science and Psychiatry and the Bell Alcohol and Addictions Endowed Chair
Today's standard of care is woefully antiquated and inadequate, with more than 90% of patients relapsing after treatment. Sophrosyne's novel compounds hold the promise of fundamentally transforming the treatment experience for the roughly 30 million patients of AUD in the U.S. and hundreds of millions more around the world.
